Pharma BD Deal Intelligence

Merck & Co. Inc. / Idenix Pharmaceuticals

2014 · Acquisition/Merger · $3.9B · Complete

Announcement Sentiment

25

Negative

Outcome Score

15

Did not work — the deal failed to deliver.

Merck acquired Idenix Pharmaceuticals for $3.85B, a hepatitis C drug developer.

Key facts

Announced Jun 09, 2014
Closed Aug 05, 2014
Deal value $3.9B
Deal type Acquisition/Merger
Therapeutic area Infectious Disease

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals